|
In association with
Abbott Global Pharmaceutical Research & Development
Why should you attend this event?
Upon completion of this workshop, you will learn many of the challenges that are pervasive in the field of FBDD including:
- Shortcomings of various screening methods and biophysical tools
- Challenges in fragment optimization
- Changing the culture: What kind of credibility does FBDD have inside your walls?
- Other "nagging" issues in the field
Who should attend this event?
Vice Presidents, Heads, Directors, Principal Scientists and Managers in the following areas
- Fragment-Based Drug Design
- Computer Assisted Drug Design
- Drug Development
- Discovery Chemistry
- R&D, Strategic Planning and Development
Scroll down for the workshop timetable.
|
What is this workshop about?
The concept of Fragment-based drug discovery has progressively become more prominent in the pharmaceutical industry. Success stories of fragment-based drug design permeate the literature and this has resulted in an appreciable number of early and late stage drug candidates. FBDD has evolved into a general approach that combines the empiricism of random screening of fragment sized molecules, along with the strategic implementation of robust biophysical tools and the rationality of structure-based design.
Although the execution and success of FBDD continues to grow, there still exist a number of challenges to the approach that continue to affect everyone in the field.
This workshop offers the opportunity to present and discuss the issues we are all facing including: general screening tools and approaches, optimization strategies, the role of computational tools, and the general acceptance of the FBDD approach.
A series of short vignettes and closed-door, unrecorded group discussion will provide additional insight into the challenges we all face and help us create a clearer view of what we can all do to advance the field.
Who is leading this workshop?
The workshop is being led by Steve Swann, Research Investigator, Fragment-Based Lead Generation, Abbott:
|
Steve began his undergraduate work at St. Francis University in rural Pennsylvania where he received a dual B.S. in Chemistry and Biology. He went on to receive his Ph.D. in Organic Chemistry under John Koh, at the University of Delaware in 2002 where he used molecular modeling to design and synthesize potentially therapeutic vitamin D analogs.
After his graduate work he moved onto to Dupont Discovery research where he continued to use computer-aided design to develop novel fungicides and insecticides for an array of protein targets.
After 5 years, Steve moved on to Abbott in 2006 where he now uses structure-based design to optimize fragment hits generated from an array of different screening approaches.
Steve serves as the head chemist in the fragment screening and lead characterization group and has worked on more than 10 fragment-based projects in the past 12 months, along with several fast-follower programs.
|
|
Workshop agenda
Thorsten Nowak, Team Leader - Medicinal Chemistry, AstraZeneca
Experience and backgrounds of participants and hosts
Purpose and scope of the workshop
Thorsten Nowak, Associate Principal Scientist, AstraZeneca UK Design of compound libraries for fragment screening Peter Kenny, Molecular Design & Drug Discovery Scientist , Freelance
Peter Kenny, Molecular Design & Drug Discovery Scientist, UK
Biophysical tools and screening methods Sachin Surade, Research Associate, Prof. Sir Tom Blundell Group, University Of Cambridge
Sachin Surade, Research Associate, Prof. Sir Tom Blundell Group, University Of Cambridge, UK
Implementation and role of FBDD at AstraZeneca Thorsten Nowak, Team Leader - Medicinal Chemistry, AstraZeneca
Thorsten Nowak, Associate Principal Scientist, AstraZeneca UK
"How are we doing anyway" : How do we implement FBDD, how do we measure success and where is it going? Samantha Hughes, Senior Principal Scientist, Computational Chemistry, Pfizer
Samantha Hughes, Senior Principal Scientist, Computational Chemistry, Pfizer, UK
copyright ©
2024
SAE Media Group
|